Search

Objectives To describe a patient with BRCA1 mutation, mucoepidermoid parotid, multiple breasts, and thyroid cancers. Case Report A women was diagnosed at 33-years-age with a triple-negative breast cancer (right breast), at 43-years-age with a triple-negative breast cancer in left breast and at 53-years-age with a primary papillary-thyroid carcinoma. At 55-years-age, she was diagnosed with a primary mucoepidermoid carcinoma in right parotid, and concomitantly, her right nipple was affected by Paget's disease and a recurrent carcinoma in right breast (HR + /HER2 = 3 +). At 57-years-age, after the recurrence of a triple-negative breast cancer (left breast), a geneticist evaluated the patient's family history, including one stomach, one non-smoking-related lung, and two smoking-related laryngeal cancers. Genetic testing revealed a BRCA1 mutation (Chr17:41:251.867). The patient's daughter (a non-cancer patient) tested negative for the mutation. Both remain under medical supervision. Conclusions We suggest that BRCA1 mutations are associated with non-breast and non-ovarian cancers such as salivary gland cancer.

INTRODUCTION: PMS1 is part of the cluster of genes related to Mismatch repair genes (MMR) and has been used for investigation in oncogenetic panels. The MMR genes play an important role in tumor control and progression, however, the role of PMS1 in this process still poorly understood and information about its role in increasing the risk of developing a hereditary cancer predisposition syndrome (SHPC) is not completely understood.AIM: To characterize clinically and genetically cancer patients with NCCN criteria for SHPC and carriers of variants in the PMS1 gene.METHODOLOGY: A total of 368 patients suspected of having SHPC, according to the National Comprehensive Cancer Network (NCCN) criteria, were investigated using a Next-Generation Sequencing (NGS) in a panel containing 31 genes. Those that showed variation in the PMS1 gene were grouped, and the tumors were characterized in clinical and molecular aspects.RESULTS: From the 368 patients analyzed, 6.8% (25/368) patients presented Variants of Uncertain Significance (VUS) in PMS1. There was a case of Breast Cancer (BC) with a variant in PMS1, not described in ClinVar, presented in heterozygosis, probably pathogenic [Chr2:190.738,325 NM_000534: c.2578delA: p.(Arg860.Glufs*14)]. Besides, this case was associated with a family history (FH) of cancer breast cancer and melanoma. It is worth mentioning that only one patient was a man, with colorectal cancer (CRC), and his FH also was CRC in addition to stomach cancer. The only change founded was the presence of VUS NM_000534:c.1615A>G:p.(Met539Val) which was identified in 32% (8/25). This VUS was the only genetic alteration observed in 20% (5/25) patients with tumors in the breast (3), thyroid (1), CRC (1), and ovary (1). One of these patients had bilateral breast cancer and thyroid tumor. The patients had their age at diagnosis ranged from 25 to 65 years, with an average of 41 years. The carriers of variants exclusively in PMS1 [40% (10/25)] had different tumors: breast (6); CRC (3); ovary (2); lymphoma (1); thyroid (1); others 32% (n = 8/25) that presented additional VUS in different genes: [ATM (2); BARD (1); CDH1 (1); CHECK2 (1); NBN (1); APC (1); POLE (1)]. Different pathogenic variants (PV) [28% (n = 7/25)] also were identified, besides the previous PMS1 VUS described. The PV was founded in ATM (1); BRCA1 (3); NF1 (1); TP53 (1); MUTYH-heterozygosis (1), and PMS1 (1) gene. A double pathogenic variation was identified in a patient (MUTYH in heterozygosis and BRCA1). The findings in PMS1, even currently classified as VUS, should highlight observation for the clinical and familiar history. Genetic panels should be increasingly used in the investigation of SPHC.CONCLUSION: The roles of PMS1 in cancer progression need further investigations. A few numbers of reports have been identified on germline PMS1 mutations, considering defined disease phenotypes. Therefore, the performance of genetic panels, including the PMS1 gene, in SHPC further investigations will expand our knowledge and permit precise genetic counseling. Citation Format: Isabelle JoyceLima Silva-Fernandes, Clarissa Gondim Picanço-Albuquerque, Maria Claudia dos Santos Luciano, Deysi Viviana Tenazoa Wong, Maria Júlia Barbosa Bezerra, Flavio Silveira Bitencourt, Francisca Fernanda Barbosa Oliveira, Paulo Goberlanio de Barros Silva, Rosane Oliveira Sant´anna, Marcos Venicio Alves Lima. Pms1 gene: A new risk-mutation description? [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS16-30.

INTRODUCTION: HBOC syndrome is directly associated with a variant in BRCA1/2 genes and the diagnosis may increase anxiety and depression levels because of the need for preventive measures. Psychic impacts on women with mutations have been further explored in the literature, although the emotional aspects linked to the diagnosis in male breast cancer is poorly known. AIM: This work aimed to compare the anxiety, depression, and quality of life levels in male and female cancer patients HBOC-suspected, immediately after the result of the genetic test. METHODOLOGY: A retrospective case-control study was carried out with five men matched for age with 39 women, both with National Comprehensive Cancer Network (NCCN) criteria for HBOC. The Hospital Anxiety and Depression (HAD) scale and the WHOQOL-bref quality of life inventory were used. Sociodemographic, clinical, molecular, and psychological data were analyzed using χ2/Fisher's exact and Mann-Whitney, Friedman/Dunn, and Wilcoxon tests (SPSS, 20.0; p 45 years old, all recruited women had breast cancer as the primary tumor and eight of them (20.5%) had ovary cancer. We had two male breast cancer and three prostate cancer Gleason>7. Sociodemographic characteristics did not differ between the genders (p> 0.05). Men had a higher prevalence of pathogenic mutation (p=0,031). Women had a higher prevalence of BRCA1 mutations (p=0,014) while men had of BRCA2 mutation (p=0,001). There was no difference in the anxiety and depression levels immediately after receiving the result, but it was observed that only women had lower quality of life in the physical domain (p=0,048). This domain showed the lowest scores in female patients (p Citation Format: Francisca Fernanda Barbosa Oliveira, Paulo Goberlanio de Barros Silva, Isabelle JoyceLima Silva-Fernandes, Clarissa Gondim Picanço-Albuquerque, Maria Claudia dos Santos Luciano, Maria Júlia Barbosa Bezerra, Rosane Oliveira Sant´anna, Flavio Silveira Bitencourt, Marcos Venicio Alves Lima. Hereditary breast and ovarian cancer syndrome (HBOC) diagnosis impacts more the life quality of women than men: A case-control report [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-37.

INTRODUCTION: The male breast cancer (MBC) is a rare disease, responsible for about 0.2% of all cancers and 0.1% of deaths for male cancer. Despite the rarity of the disease, statistics indicate that the incidence of MBC has been increasing significantly. The main risk factors for the development of MBC include old age, hormonal imbalance, radiation exposure, and family history of breast cancer. Hereditary breast and ovarian cancer (HBOC) is a syndrome associated with mutations in the BRCA1 and BRCA2 genes that have been related to MBC that as a rare disease, still poorly understood. METHODOLOGY: Family history analyzes, type and tumor staging, molecular markers expression, hormone receptors (RE, RP, and HER2), and cell proliferation marker (KI67) analysis were performed by immunohistochemistry. The presence of genetic mutations and the frequency of these mutations were evaluated in 31 genes of HBOC suspected patients treated at the Haroldo Juaçaba Hospital between the years 2009 to 2020. RESULTS: A total of 236 patients were diagnosed with breast cancer and submitted to a genetic test. Six of them were male patients aged between 54 and 73 years. His family history indicated that 83.3% had first-degree relatives affected by breast cancer. Different pathological staging was founded after tumors evaluation with the presence of micrometastases (P3) and higher levels of invasion in the lymph nodes. The expression of the cell proliferation marker (KI67) indicated low levels of expression except for patient P5. All patients presented expression of two hormone receptors (ER and RP) and no expression for HER2, except for one patient (P1), who had bilateral breast cancer, with HER2 expression (+2) on the right breast (first tumor) and no RP and HER2 expression in the left breast (second tumor), besides a moderate expression of KI67 (40%) (Table 1). The oncogenetic evaluation indicated that 83.33% of the patients had mutations described in the clinical database (ClinVar) 60% of them were pathogenic. The variants founded were in the PALB2 (16.66%), BRCA1 (33.33%), and BRCA2 (33.33%) genes (Table 1). The pathogenic mutations founded were located in the BRCA 1 and BRCA2 genes. One patient (P5) did not present mutations or VUS. The patient without the mutation (P5) presented a tumor with T3N1 pathological staging, low expression of estrogen (10%) and progesterone (10%) receptors, absence of HER2 expression, and high capacity of proliferation, indicated by the expression of KI67 (80%). The results indicate heterogeneity in the histological and molecular patterns of the patients evaluated, besides the oncogenetic patterns that may be associated with HBOC, especially those whose variants founded were pathogenic.CONCLUSION: Due to the low frequency of male breast cancer, the oncological data of these patients are relevant for epidemiological, pathological, and oncogenetic characterization, improving the characterization and identification of patterns for this pathology.Research Sponsor: Ministerio da Saude, Brasil (PRONON) Table 1. Histopathologic molecular markers and variation gene characterization of male breast cancer evaluated in Hospital Haroldo Juaçaba, Northest of Brazil, between 2009 and 2020. *VUS #Pathogenic variation.AgeFamiliar historyMolecular markersVariationPatientDiagnosticLast clinical evaluationBCOtherSubtype tumorPathological stagingRERPHER2KI67GeneSpecificityP14857YesPancreas; CCPLUMINAL A(R) pT1cpN1a(L) pT1B(R) 80%(L) 80%(R) 20%(L) negative(R) +2(L) negative(R) 18%(L) 40%PALB2*c. 3257G>A:Arg1086GlnP27274YesNoLUMINAL B(L)pT2 pN3a90%100%Negative20%BRCA1*c. 754C>T:Arg252CysP36466NoNoLUMINAL ApT2pN1mic90%70%Negative10%BRCA1#c. 5266dupC: p.Gln1756Pro fs74P45457YesNoLUMINAL A(L)T4bN290%90%Negative10%BRCA2#c. 4808delA: pAsn1603Thr fs14P55858YesProstaticLUMINAL A(R) T3N110%10%Negative80%Not detectedNot detectedP65858YesProstaticLUMINAL B(R) T4dN060%60%Negative30%BRCA2#c. 4808delA: pAsn1603Thr fs14 Citation Format: Maria Claudia dos Santos Luciano, Maria Júlia Barbosa Bezerra, Isabelle JoyceLima Silva-Fernandes, Paulo Goberlanio de Barros Silva, Clarissa Gondim Picanço-Albuquerque, Rosane Oliveira Sant´anna, Francisca Fernanda Barbosa Oliveira, Flavio Silveira Bitencourt, Marcos Venicio Alves Lima. Oncogenetic caracterization and imunohistochemistry patterns of male cancer breast diagnosticated in Haroldo JuaÇaba hospital, Northeast of Brazil [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-27.

Emotional distress associated with genetic testing for hereditary breast and ovarian cancer syndrome (HBOC) is reported to interfere with adherence to treatment and prophylactic measures and compromise quality of life. To determine levels of anxiety, depression, and quality of life in patients tested for pathogenic BRCA1/2 mutations and identify risk factors for the development of adverse psycho-emotional effects. Cross-sectional observational trial involving 178 breast or ovarian cancer patients from a referral cancer hospital in Northeastern Brazil. Information was collected with the Hospital Anxiety and Depression Scale (HADS) and the World Health Organization (WHO) Quality of Life (QoL) questionnaire (WHOQOL-BREF). Patients suspected of HBOC had higher levels of anxiety than depression. The presence of (probably) pathogenic BRCA1/2 mutations did not affect levels of anxiety and depression. High schooling, history of psychiatric disease, and use of psychotropic drugs were directly associated with high anxiety. High schooling was too inversely associated with QoL as such a breast tumor. Anxiety and depression were directly correlated and both reduced significantly QoL. Our results highlight the importance of psychological support and screening of risk factors for anxiety and depression and low QoL in HBOC patients at the time of testing.

Background Penile cancer is one of the most aggressive male tumors. Although it is preventable, the main etiologic causes are lifestyle behaviors and viral infection, such as human papillomavirus (HPV). Long-term epigenetic changes due to environmental factors change cell fate and promote carcinogenesis, being an important marker of prognosis. We evaluated epidemiological aspects of penile squamous cell carcinoma (SCC) and the prevalence of HPV infection using high-risk HPV (hrHPV) and p16INK4A expression of 224 participants. Global DNA methylation was evaluated through 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). Results The incidence of HPV was 53.2% for hrHPV and 22.32% for p16INK4a. hrHPV was not related to systemic or lymph node metastasis and locoregional recurrence, nor influenced the survival rate. P16INK4a seems to be a protective factor for death, which does not affect metastasis or tumor recurrence. Lymph node and systemic metastases and locoregional recurrence increase the risk of death. An increased 5mC mark was observed in penile SCC regardless of HPV infection. However, there is a reduction of the 5hmC mark for p16INK4a + (P = 0.024). Increased 5mC/5hmC ratio (> 1) was observed in 94.2% of penile SCC, irrespective of HPV infection. Despite the increase in 5mC, it seems not to affect the survival rate (HR = 1.06; 95% CI 0.33–3.38). Conclusions P16INK4a seems to be a good prognosis marker for penile SCC and the increase in 5mC, an epigenetic mark of genomic stability, may support tumor progression leading to poor prognosis.

Brazilian Somalis is a locally-adapted breed of rams raised in tropical climate and native pastures. The present study was conducted to evaluate gene expression and proteome of the reproductive tract of such rams. Samples were collected from testes, epididymides, seminal vesicles and bulbourethral glands of four rams. Expression of clusterin (CLU), osteopontin (OPN) and prostaglandin D2 synthase (PGDS) genes were evaluated in all samples by real-time PCR. Shotgun proteomic analysis was performed using samples from the head, corpus and cauda epididymides and from all other structures as well. Gene ontology terms and protein interactions were obtained from UniProtKB databases and MetaCore v.6.8 platform. CLU trasncripts were detected in the testes, epididymides, seminal vesicles and bulbourethral glands of the Somalis rams. The initial region and body of the epididymis had the greatest CLU expression. OPN mRNA was localized in all tissues of the ram reproductive tract. PGDS mRNA was detected in the testes and epididymides. Lable-free mass spectrometry allowed the identification of 137 proteins in all samples. Proteins of the epididymis head mainly participate in cellular processes and response to stimulus, participating in catalityc activity and binding. Proteins of epididymis body acted as regulatory proteins and in cellular processes, with binding and catalytic activity. Cauda epididymis molecules were associated with cellular processes and regulation, with binding function and catalytic activity as well. Testis proteins were mainly linked to cell processes and response to stimuli, and had catalytic function. Seminal vesicle proteins were involved in regulation and mainly with binding functions. Most bulbourethral gland proteins participated in cellular processes. The present study is the first to evaluate the proteome and gene expressions in the reproductive tract of Brazilian Somalis rams. Such pieces of information bring significant cointribution for the understanding of the reproductive physiology of locally-adapted livestock.

Made available in DSpace on 2021-06-25T11:23:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-04-01 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (FUNCAP) The aim of this study was to characterize the protein profile of ovarian follicular fluid (FF) of brown brocket deer (Mazama gouazoubira). Five adult females received an ovarian stimulation treatment and the FF was collected by laparoscopy from small/medium (3.5 mm) follicles. Concentrations of soluble proteins in FF samples were measured and proteins were analyzed by 1-D SDS-PAGE followed by tryptic digestion and tandem mass spectrometry. Data from protein list defined after a Mascot database search were analyzed using the STRAP software tool. For the protein concentration, no significant difference (P> 0.05) was observed between small/medium and large follicles: 49.2 +/- 22.8 and 56.7 +/- 27.4 mu g/mu l, respectively. Mass spectrometry analysis identified 13 major proteins, but with no significant difference (P> 0.05) between follicle size class. This study provides insight into elucidating folliculogenesis in brown brocket deer. Univ Estadual Ceara, Fac Vet, Av Dr Silas Munguba 1700, BR-60714903 Fortaleza, Ceara, Brazil Univ Fed Ceara, Dept Anim Sci, Fortaleza, Ceara, Brazil Univ Estadual Ceara, Hlth Sci Ctr, Fortaleza, Ceara, Brazil Univ Fed Ceara, Lab Mass Spectrometry, Fortaleza, Ceara, Brazil State Univ Sao Paulo, Dept Anim Sci, Jaboticabal, Brazil Univ Ctr Fametro, Mol Genet Res Unit, Fortaleza, Ceara, Brazil State Univ Sao Paulo, Dept Anim Sci, Jaboticabal, Brazil CNPq: 461330/2014-8 (FUNCAP): CI3-0093-0005580100/14

e20548 Background: Lung cancer has the highest incidence and mortality worldwide. In Brazil, it is the second most common, and individualized therapy, although more efficient than traditional chemotherapy, is still a challenge for health services, especially in developing countries, as socioeconomic disparities make access to genetic testing difficult or treatment. Thus, it is understood that greater knowledge about the genetic profile and therapeutic response of different populations can contribute to policy changes that guarantee expanded access to individualized therapy. Methods: the EGFR gene mutation status was correlated with clinical-epidemiological, socioeconomic, treatment, and survival parameters of patients with lung adenocarcinoma treated from 2014 to 2021 at an oncology referral center in northeastern Brazil. Data were obtained retrospectively from the patient's charts at the Hospital Haroldo Juaçaba/Instituto do Câncer do Ceará. The X²/Fisher and Log-Rank Mantel-Cox tests were used to associate clinical variables and overall survival curves. The Research Ethics Committee approved the research under protocol number 3.544.754. Results: 586 patients tested, 157 (26.8%) had an EGFR mutation, with exon 19 deletion (n = 83, 52.9%). the most frequent followed by L858R (n = 54, 34.4%) and others (n = 30, 12.8%). The EGFR mutation was inversely associated with smoking history (p < 0.001) and previous use of carboplatin plus paclitaxel (p < 0.001). The median overall survival was 33 (95%CI = 25-41) months, and the presence of a mutation was not associated with a worse outcome (p = 0.146). Interestingly, patients with sensitivity mutation who used gefitinib (64.1%) did not show a significant difference in overall survival (p = 0.218). However, when stratifying analyzes according to mutation type, it was observed that patients with exon 19 deletion treated with gefitinib had greater median overall survival (32, 95%CI = 27-37 months) than patients with this mutation not treated with gefitinib (median = 15, 95%CI = 2-25 months) (p < 0.001). Patients with the L858R type sensitivity mutation (p = 0.523) or other mutations (p = 0.439) did not experience significant benefits from gefitinib use. Conclusions: In the population studied, the exon 19 deletion was the most frequent and the only one associated with a substantial benefit from using gefitinib.

e22529 Background: Genetic tests have been increasingly requested to identify families at risk of hereditary cancer. In a family with a known mutation, the offspring of a carrier, whether male or female, have a 50% risk of inheriting the mutation. Most studies on the psychological implications associated with genetic testing have focused on women and few studies have focused on the male population. Methods: A total of 56 men with a personal history of cancer underwent screening for mutations in a panel of 31 genes associated with hereditary cancer. Assessment of quality of life (QoL) and levels of anxiety and depression was performed after patients received the genetic test result. For this, the HADS and WHOQOL-BREF scales were used. Wilcoxon, X², and Spearman correlation tests were used (SPSS v20.0 for Windows). Results: Of the 56 participants, 28.6% had a pathogenic mutation, 32.1% had a Variant of Undetermined Significance (VUS), and 39.3% had no mutation. The presence of the mutation was not associated with QoL (p = 0.967) or anxiety (p = 0.436) or depression (p = 0.945). Mean QoL was 77.95±7.38 (range = 50.00-95.20), mean anxiety was 5.14±2.62 (range = 1-14) and mean depression scores were 4.14±2.55 (range = 0-14). QoL was inversely correlated with levels of anxiety (p < 0.001, r = -0.496) and depression (p < 0.001, r = -0.494), parameters that were directly correlated (p = 0.037, r = 0.279). Most patients had QoL > 80 (n = 38, 67.9%), and only 16 (28.6%) and 13 (23.2%) men had HAD scores > 5. Conclusions: The result of carrying a mutation did not influence the quality of life and anxiety or depression levels in the male population evaluated. However, it was observed that levels of anxiety and depression can compromise the quality of life. The data from the present study reinforce the importance of considering the psychological aspects in the process of genetic investigation for hereditary cancer. In addition, it suggests that educational levels must be investigated to assess whether the low levels of anxiety and depression observed are associated with a low level of understanding of the clinical significance of carrying a pathogenic mutation.

e22528 Background: The familiar history is indispensable to clinical investigation during genetic counseling and the new molecular techniques allowed the identification of hereditary cancer predisposition syndromes (CPS). However, the classification systems of these syndromes are difficulty and very complex. In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines for the assessment of variants in genes associated with Mendelian diseases to reduce the subjectivity bias of mutation variants classified as risk. Methods: To show the difficulty of classification of these variants we describe a case report of a family from countryside of Brazil in which there is a high rate of inbreeding. This family has three brothers with polyposis and colorectal cancer between 51 and 60 years-old. Results: The index-case had multiple polyps, developed colorectal cancer at 51 years-old and had a familiar history of two brother dead by colorectal cancer after polyposis and nine brother without familiar history of cancer, a father dead at 38 years-old by non-specific lung-disease and a mother alive at 83 years-old. There was no description of other cases of cancer among uncles and grandparents. The index-case performe a NSG genetic painel to CPS and showed a homozygosis variant in MUTYH gene: NM_001048174.1: c.253T > C:p.(Trp85Arg), that was classified as variant of uncertain significance (VUS). MUTYH is a base excision repair enzyme, it plays a crucial role in the correction of DNA errors and may be considered a cell protective factor and is associated with MUTYH-related polyposis (MAP). MAP is an autosomal recessive CPS and presents a phenotype that overlaps attenuated polyposis and familial adenomatous polyposis, increasing the risk of colorectal cancer in 43-63% up to 60 years or 80% if there is no surveillance/tracking. In view of the family history that suggests autosomal recessive inheritance, with a homozygous variant absent in the database of population controls (gnomAD) and in which in silico predictors indicate the effect of this variant as deleterious, the management of this family must be carried out considering it as a potential high-risk pathogenic variant. Conclusions: While the classification criteria for the variants are being refined, we reinforce the importance of a careful family history in the approach to CPS in order to offer an appropriate clinal conduct in the prevention of hereditary cancer.

Metal-based compounds have emerged as a novel strategy to improve our arsenal of medicines. Among these compounds, carbon monoxide donor agents have been developed mainly as metal complexes. These compounds have shown exciting biological activities, among them strong anti-inflammatory, antibiotic, and anticancer activity, although some of those properties might be associated with the metal moiety as well. Aiming to prepare a new ruthenium complex containing CO, we prepared a cis-[RuCl(CO)(dppb)(dppz)]PF6 complex (dppb = 1,4-bis(diphenylphosphino)butane and dppz = dipyrido[3,2-a:2′,3′-c]phenazine), which was fully characterized along with DFT studies. This compound exhibited great thermal stability in phosphate buffer solution, but showed fast and efficient release of CO upon light irradiation, including blue LED. Surprisingly, DNA binding was quite weak, despite the dppz ligand moiety, suggesting that steric effects prevented intercalation binding. Nonetheless, this compound exhibited promising antibiotic activity against S. aureus, S. epidermidis and C. albicans in a low micromolar range. However, there was no further improvement upon light irradiation suggesting that there is no role of CO. Additionally, cytotoxicity assay using cancer cells showed quite low IC50 (92 nM, HCT-116) along with moderate to low toxicity assayed in lymphocytes and Artemia. Altogether, these results supported that this compound has great potential as a biological agent, whereas neither CO release nor DNA binding seemed to have a direct role in its activity.

e13670 Background: Loss-of-function mutations in PALB2 gene are associated with increased risk for breast cancer and possibly pancreatic, ovarian, male breast, prostate, colorectal as others cancers. In Brazil it has been estimated that up to 1,516 new cases of hereditary breast cancer for 2020 in the North and Northeast regions. Analysis of susceptibility gene mutations helps identify precisely the high-risk patient and their families, whom need specific and personalized clinical management as high-risk individuals. Methods: Twenty-six patients with pathogenic mutations in PALB2 gene identify by next-generation sequencing from states of Bahia (11), Ceará (9), Pernambuco (5) and Rondônia (1) in the North and Northeast regions were analyzed. Results: Most of the patients analyzed had only breast cancer (80%), including two cases of male breast cancer (9,5%); the others were isolated cases of endometrial cancer (4%), breast and pancreas cancers (4%), breast and lung cancers (4%), only ovarian cancer (4%) and ovarian and breast cancers (4%). Most cancers were stage II or III (65%). Family history of cancer was observed in 22/26 (84%); the most common tumors were breast, prostate, pancreas and thyroid. The founder mutations were more frequent in exons: 4 (58%) and 12 (15%). Eleven variants were found as follow: c.1240C > T (19%); c.3256delC (15%); c.1671_1674delTATT (11.5%); c.355delC (11.5%); NC_000016.9:g.(?_23632673)_(23652488_?)del (11,5%). The greatest variety of mutations was found in the state of Bahia, probably due to the greater number of patients included (42%). Conclusions: These data suggest that changes in clinical management of PALB2 patients are needed since the phenotype observed exhibited pattern of hereditary tumors, including male breast cancer. Besides that, PALB2 gene should be included in painel gene analysis in patients from the North and Northeast of Brazil because its high frequency of pathogenic variants.

e13532 Background: The Lynch syndrome (LS) is the most common inherited syndrome associated with colorectal cancer (CRC). The hallmark of LS is DNA mismatch repair deficiency. The amount of variants of uncertain significance (VUS) in suspected LS confounds diagnosis, requiring surveillance of variant reclassifications. In this paper we describe a new and most likely pathogenic VUS in PMS2. Methods: Patient screened for personal and familial cancer and evaluated with NGS gene panels for 31 genes. The protein structure was analyzed with the software Pymol. Results: A woman diagnosed with breast cancer (BC) at 60 years and CRC at 65 years was investigated due to her extensive family history of cancer (21 maternal relatives), including 6/9 siblings [gastric n = 1, lung n = 1, BC n = 4 (one of whom with BC, endometrium and CRC)], 8/12 aunts and uncles, all of whom died of cancer (gastric n = 4, CRC n = 1, CNS n = 1, BC n = 1; uterus/gallbladder n = 1), and 7 cousins (CNS n = 3, lung n = 1, gastric n = 2, suspected ovary n = 1). The new PMS2 gene variant c.134A > G(p.Asn45Ser), which was also detected in two sisters with CRC submitted to segregation analysis, occupied the same locus as a known pathogenic variant, c.134A > C(p.Asn45Thr). The structural analysis showed that the mutated locus encodes a serine instead of an asparagine in position 45 at the enzyme’s active site. Asn 45 is a conserved amino acid that binds to ATP in protein structure (PDB = 1EA6). Interestingly, this is close to position 42-44, for which another potentially pathogenic VUS (p.Leu42_Glu44del) has been described. Conclusions: Based on our patient’s personal and family history and on the locus variant and protein structure analysis, the new PMS2 gene variant described in this paper is most likely pathogenic.

e13603 Background: Identifying carriers of hereditary cancer predisposition syndromes (HCPS) improves prevention and treatment. However, due to the elevated cost of genetic testing, information on the prevalence and incidence of HCPS is scarce, depriving patients of assertive treatment―a scenario observed worldwide, especially in regions like Northeastern Brazil. In this study, we determined the prevalence of hereditary breast and ovarian cancer (HBOC) in patients from Ceará (Brazil) based on NCCN criteria. Methods: The patients (n = 267) were evaluated using NGS gene panels, while retrospective data were analyzed statistically with the chi-squared test, Fisher’s test and multinomial logistic regressions ( p< 0.05; SPSS 20.0). Results: BRCA1/2 was detected in 21.3% (57/267) of the sample, but BRCA1 was more prevalent than BRCA2 (70%; 40/57 vs 30%; 17/57) ( p< 0.001). Having two or more primary tumors ( p= 0.031) or primary ovarian cancer ( p= 0.029) was associated with the pathogenic mutation BRCA1/2. The latter was detected in patients with bilateral tumors (40%) and male breast cancer (45%), and in patients under 45 years (67%), with familial breast cancer (27%) and familial ovarian cancer (41%). In the multivariate analysis, the triple-negative phenotype was strongly associated with mutated BRCA1/2 ( p= 0.003). Conclusions: The prevalence of HBOC in our sample is compatible with rates reported worldwide. The study variables (bilaterality, male sex, age < 45 years, family history of breast or ovarian cancer, and triple-negative phenotype) reinforce the diagnostic criteria published by the NCCN.

e13602 Background: Breast cancer (BC) is associated with several hereditary syndromes (HS). Patients with clinical criteria for hereditary breast and ovarian cancer (HBOC) should be evaluated for the presence of pathogenic BRCA1/2 variants, although the absence of BRCA1/2 variants does not rule out HS. The purpose of this study was to evaluate the prevalence of pathogenic non- BRCA1/2 variants in patients with suspected HBOC. Methods: Suspected HBOC (NCCN criteria) patients (n = 267) from a Northeastern Brazilian referral cancer hospital were submitted to NGS 31-gene painel. Individuals testing negative for BRCA1/2 mutation (n = 210) remained in the present presentation. Data were analized by the chi-squared test and Fisher’s test ( p< 0.05; SPSS 20.0). Results: Pathogenic/likely pathogenic (P/LP) non- BRCA1/2 variants were detected in 13.3% (n = 28/210) of the patients, all of whom had BC. The most prevalent variant was PALB2 (31%), followed by ATM and MUTYH (14.2%), and TP53 and PMS2 (10.7%). Among these patients 10.7% (n = 3/28) had triple negative tumors. Other gene variants ( BARD1, CHEK2, MLH1, MSH2, PMS1 and XRCC2) were observed at lower frequencies (3.5% each). DNA mismatch repair (MMR)/Lynch syndrome (LS) mutated genes were identified in 4/24 patients with BC. Rare microdeletions were identified in PALB2 (chr16:23652431-23652678 [exons 1-10] and TP53 (chr17:7.573.927-7.579.891 [exons 2-10]) , to our knowledge for the first time in the medical literature (ClinVar). In addition, one patient displayed a double pathogenic variant in ATM (c.67C > T: p.[Arg23*]) and PALB2 (chr16:23652431-23652678 [exons 1-10]). Patients with and without P/LP did not differ with regard to clinical-pathological parameters or therapeutic profile. Conclusions: Patients with suspected HBOC should be evaluated for non- BRCA1/2 variants, including MMR. We also suggest considering BC among the malignancies associated with LS.

The present study was conducted to describe the major seminal plasma proteome of rabbits and potential associations between seminal proteins and semen criteria. Semen samples were collected from 18 New Zealand adult rabbits, and seminal plasma proteins were analyzed by 2-D SDS-PAGE and tandem mass spectrometry. Sperm motility, vigor, concentration, morphology and membrane sperm viability were evaluated. Rabbits ejaculated 364 ± 70 million sperm/ml, with 81 ± 6.1% motile cells, 3.8 ± 0.2 vigor and 66.7 ± 2.5% sperm with normal morphology. Based on the viability and acrosome integrity assay, there were 65.8 ± 2.5% live sperm with intact acrosome and most spermatozoa had both intact acrosome and functional membrane. On average, 2-D gels of rabbit seminal plasma had 232 ± 69.5 spots, as determined by PDQuest software (Bio Rad, USA). Mass spectrometry allowed the identification of 137 different proteins. The most abundant proteins in rabbit seminal plasma were hemoglobin subunit zeta-like, annexins, lipocalin, FAM115 protein and albumin. The intensity of the spots associated with these five proteins represented 71.5% of the intensity of all spots detected in the master gel. Multiple regression models were estimated using sperm traits as dependent variables and seminal plasma proteins as independent ones. Also, sperm motility had positive association with beta-nerve growth factor and cysteine-rich secretory protein 1-like and a negative one with galectin-1. The percentage of rabbit sperm with intact membrane was related to seminal plasma protein FAM115 complex and tropomyosin. Then, the population of morphologically normal sperm in rabbit semen was positively linked to carcinoembryonic antigen-related cell adhesion molecule 6-like and down regulated by seminal plasma isocitrate dehydrogenase. Based on another regression model, the variation in the percentage of live sperm with intact acrosome was partially explained by the amount of leukocyte elastase inhibitor and the peptidyl-prolyl cis-trans isomerase A in the rabbit seminal fluid. The current study reports the identification of 137 proteins of rabbit seminal plasma. Major proteins of seminal secretion relate primarily to prevention of damages caused by lipid peroxide radicals and oxidative stress, membrane functionality, transport of lipids to the sperm membrane and temperature regulation. Moreover, finding seminal plasma proteins as indicators of semen parameters will improve assisted reproductive technologies.

Molecular components of sperm and in the media surrounding them influence male fertility. In this regard, seminal plasma proteins and metabolites modulate various reproductive events, including sperm motility and capacitation, cell protection, acrosome reaction, fertilization and embryonic development. Empirical associations between seminal proteins and metabolites and fertility indicate that these molecules are potential molecular markers of male reproductive status in cattle and other species.